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INTRODUCTION
Widespread emergence of methicillin-resistant Staphylo-
coccus aureus (MRSA) since the 1980s has led to the popular
use of glycopeptides in clinical practice for more than 20 yr.
Since the first report of vancomycin-intermediate S. aurues
(VISA) in Japan (1), more than 20 cases of VISA infections
have been reported (2). Furthermore, three isolates of van-
comycin-resistant S. aureus (VRSA) (minimal inhibitory con-
centration [MIC] ≥32 mg/L) which had been reported since
2002 from the United States added more serious concern
(3-5). Another category of decreased susceptibility to gly-
copeptide is heterogeneous resistance to vancomycin (hetero-
VISA). Isolates of hetero-VISA have been reported from vari-
ous parts of the world (6-10). Although clinical relevance of
hetero-VISA is yet determined (11-14), this could be regard-
ed as an early stage to vancomycin resistance (2, 15). Prudent
use of vancomycin as well as the development of alternative
therapeutic options against MRSA is required to prevent the
further emergence of vancomycin-nonsusceptible S. aureus. 
Arbekacin, a derivative of the aminoglycoside dibekacin
(16), has been reported to have good in vitro activity against
Gram-positive bacteria including MRSA (17, 18). Previous
reports showed that the majority of MRSA isolates in Europe
and Japan were susceptible to arbekacin (19). Combination
of arbekain and vancomycin also showed a synergistic inter-
action against MRSA in vitro (20). However, there have been
no reports about efficacy of arbekacin-based combination
regimens against S. aureus with reduced susceptibility to van-
comycin, particularly hetero-VISA. 
In this study, we investigated the in vitro activities of
arbekacin-based combination regimens with vancomycin,
teicoplanin, rifampin, ampicillin-sulbactam, or quinupristin-
dalfopristin against hetero-VISA isolated from Korea, Japan,
and India. 
MATERIALS AND METHODS
Bacterial strains 
Seven isolates of hetero-VISA from clinical specimens were
used in this study. Four isolates were from Korea (K1272,
K1299, K193, and K237), two from Japan (Mu3 and J51),
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Synergy of Arbekacin-based Combinations Against Vancomycin
Hetero-intermediate Staphylococcus aureus 
This study was undertaken to evaluate the in vitro activities of arbekacin-based
combination regimens against vancomycin hetero-intermediate Staphylococcus
aureus (hetero-VISA). Combinations of arbekacin with vancomycin, rifampin, ampi-
cillin-sulbactam, teicoplanin, or quinipristin-dalfopristin against seven hetero-VISA
strains and two methicillin-resistant S. aureus strains were evaluated by the time-kill
assay. The combinations of arbekacin with vancomycin, teicoplanin, or ampicillin-
sulbactam showed the synergistic interaction against hetero-VISA strains. Data
suggest that these arbekacin-based combination regimens may be useful candi-
dates for treatment options of hetero-VISA infections. 
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and one from India (I93). Two vancomycin-susceptible MRSA
strains (MRSA120 and MRSA202) were also tested. All nine
strains were resistant to oxacillin. Reduced susceptibility to
vancomycin of S. aureus isolates was confirmed by the method
of population analysis as previously described (1). Hetero-
VISA was defined as a strain that contained subpopulations
of cells that grew on the 4 mg/L vancomycin plate at a fre-
quency of 10-6 or higher (1).
Antimicrobial agents used in this study
Six antimicrobial agents were used in the in vitro suscep-
tibility test and time-kill assay ; arbekacin (Meiji-Seika Co.
Ltd., Tokyo, Japan), vancomycin (Sigma, St. Louis, MO.,
U.S.A.), rifampin (Sigma), ampicillin-sulbactam (Pfizer Phar-
maceuticals Korea, Ltd., Seoul, Korea), teicoplanin (Sigma),
and quinupristin-dalfopristin (Rhone-Poulenc Rorer, PE,
U.K.). 
Determination of MIC and MBC
MICs were determined by broth microdilution method of
the National Committee for Clinical Laboratory Standards
(NCCLS) (21). MIC determinations were performed using
cation-adjusted Muller-Hinton broth (CAMHB). The mini-
mal bactericidal concentrations (MBCs) were determined by
subculture of wells with no visible growth after MIC deter-
mination. From each microtiter wells, 0.1 mL aliquots were
cultured on blood agar plates (Becton-Dickinson, Sparks,
MD, U.S.A.) and colonies were counted after 18-24 hr incu-
bation at 37℃. The MBC was defined as the lowest con-
centrations of antibiotics that reduced the inoculums by ≥
99.9% (21). All assays were performed in duplicate.
Time-kill assay
Time-kill assay was performed with the modified method
of Watanabe et al. (14). For time-kill assay, antimicrobial
agents were used at concentrations of 0.5× and 1× MIC.
Time-kill assay was performed in CAMHB with isolates of
1.5×106 colony-forming unit (CFU)/mL. A 0.1 mL suspen-
sion of each isolates was added to 5 mL of CAMHB with
each antibiotics. Bacterial culture tubes were incubated at
37℃ with constant shaking for 24 hr. Arbekacin and other
antimicrobial agents were tested alone, or in combination,
at concentrations of 0.5× and 1× MIC. Teicoplanin and
quinupristin-dalfopristin were not tested against 2 MRSA
strains. Aliquots (0.1 mL) of bacterial culture were removed
from cultures at 0, 4, 8, and 24 hr. Each aliquot was serially
diluted in sterile saline and plated on to blood agar plates;
colonies were counted on plates yielding 10-100 colonies
after incubation at 35℃ for 24 hr. The minimum detection
limit when plating 0.1 mL of bacterial culture is about 2
log10 CFU/mL. Tests were performed in duplicate; results are
expressed as mean log10 CFU/ mL. Synergy and additivity/
indifference were defined, respectively, as a ≥2 log10 CFU/
mL decrease and a <2 log10 CFU/mL change in the average
of viable count at 24 hr for organisms treated with the com-
bination, in comparison with the most active single drug.
Antagonism is a negative interaction; the combined effect
of the drug being examined is significantly less than their
independent effect (22). The killing activities of various antibi-
otic regimens were expressed as log10 CFU/mL changes in
the number of surviving bacteria after incubation for 0, 4,
8, and 24 hr. Serial dilution of plated samples coupled with
filtration using a 0.45 micron filter was performed to mini-
mize antimicrobial carryover effect (23). 
Statistical analysis
Mean bacterial concentrations in each regimen were com-
pared by one-way analysis of variance with the post-hoc test
for multiple comparisons (SPSS, release 11.0; SPSS Inc.,
Chicago, IL, U.S.A.). A p-value of <0.05 was considered
significant.
RESULTS
MICs and MBCs
The MICs and MBCs of arbekacin, vancomycin, rifampin,
Antibiotics
MIC (MBC) (mg/L)
Isolates of hetero-VISA Isolates of MRSA
Mu3 K1272 K1299 K193 K237 J51 I93 MRSA120 MRSA202
Arbekacin 4 (16) 4 (32) 4 (16) 0.5 (4) 0.25 (1) 0.25 (1) 2 (8) 2 (4) 2 (8)
Vancomycin 2 (8) 1 (8) 1 (8) 2 (8) 2 (8) 2 (8) 2 (8) 0.5 (1) 1 (2)
Rifampin 0.125 (0.25) 0.06 (0.125) 0.125 (0.12) 0.06 (0.125) 0.06 (0.125) 0.125 (0.25) 0.06 (0.125) 0.06 (0.06) 0.06 (0.06)
A/S 8/4 (16/8) 4/2 (4/2) 4/2 (4/2) 8/4 (8/4) 8/4 (16/8) 4/2 (16/8) 1/0.5 (1/0.5) 4/2 (8/4) 4/2 (16/8)
Teicoplanin 2 (4) 2 (4) 2 (8) 8 (16) 4 (8) 8 (16) 2 (8) ND ND
QDA 0.5 (1) 0.5 (0.5) 0.5 (1) 1 (2) 1 (2) 1 (2) 0.5 (1) ND ND
Table 1. MICs and MBCs of antibiotics for hetero-VISA and vancomycin-susceptible MRSA strains
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ampicillin-sulbactam, teicoplanin, and quinupristin-dalfo-
pristin for nine stains are represented in Table 1. All nine
strains were oxacillin-resistant and their mecA genes were
confirmed by PCR method (data not shown). The MICs and
MBCs of arbekacin ranged from 0.25 to 4 mg/L and from 1
to 32 mg/L, respectively. The MIC : MBC ratios of arbekacin
ranged from 2 to 8, indicating no antimicrobial tolerance.
No tolerant strains for the other antimicrobials were found. 
Time-kill assays
Single regimen of arbekacin resulted in re-growth of 4
hetero-VISA (K193, Mu3, J51, and I93) and 2 MRSA strains
after 8 hr. The combination regimens of arbekacin with van-
comycin, ampicillin-sulbactam, or teicoplanin were syner-
gistic against strains of MRSA and hetero-VISA either at
both concentrations (0.5× and 1× MIC) or at 1× MIC
(Table 2). Combination of arbekacin and vancomycin showed
the synergistic killing effect in all strains of hetero-VISA and
MRSA except one (MRSA120). Combination of arbekacin
and rifampin showed the synergistic killing effect in only
three hetero-VISA (K1272, K1299, and Mu3) strains and one
MRSA strain (MRSA120). Combination of arbekacin and
teicoplanin or ampicillin-sulbactam was synergistic against
4 strains out of 7 hetero-VISA strains. The combination of
arbekacin and quinupristin-dalfopristin was not synergistic
against all 7 hetero-VISA. Fig. 1 showed the bacterial killing
effect of arbekacin based combination regimens at 0.5×and
1×MIC concentrations against a representative hetero-VISA
strain, Mu3. Antagonistic interaction was not observed in
any combination regimens. The combination of arbekacin
and ampicillin-sulbactam was the most effective significantly
at 1× MIC concentration against 5 strains out of 7 hetero-
VISA strains (p<0.05). At 0.5× MIC concentration, how-
ever, the combination of arbekacin and vancomycin was the
most effective significantly against 4 hetero-VISA strains
(p<0.05) (Table 2). 
DISCUSSION
Data from this study suggest that arbekacin-based com-
bination regimens could be an alternative option for glyco-
peptides in the treatment of MRSA or hetero-VISA infec-
tions. Although clinical implications of hetero-VISA are still
controversial, some reports documented the clinical failures
of vancomycin treatment in patients infected by these strains
(11, 12, 24). To treat infections caused by vancomycin non-
susceptible S. aureus, some of the current antibiotics are still
effective including rifampin, tetracycline, minocycline, chlo-
ramphenicol, trimethoprim-sulfamethoxazole, linezolid or
quinupristin-dalfopristin (25, 26). Arbekacin has been used
for the treatment of MRSA infections since 1990 in Japan
(17, 18, 27). Combination of arbekacin and ampicillin-sul-
bactam is one of the popular regimens in the treatment of
MRSA infections in Japan (28). Although arbekacin showed
relatively good in vitro activity against MRSA and hetero-
VISA, the administration of a single arbekacin of 0.5×or 1×
MIC concentrations seems not effective due to bacterial re-
growth after 8 hr in this study. As MIC:MBC ratios of arbe-
Strain
Reduction in bacterial counts (log10 CFU/mL±SD ) compared with the two antibiotics used alone
VAN+ABK
0.5×MIC 1×MIC
RFP+ABK
0.5×MIC 1×MIC
A/S+ABK
0.5×MIC 1×MIC
TEI+ABK
0.5×MIC 1×MIC
QDA+ABK
0.5×MIC 1×MIC
Mu3 -4.6± S -2.7± S- 0 . 4 ± A- 2 . 2 ± S- 2 . 2 ± S -3.8± S -1.0± A- 2 . 5 ± S- 0 . 0 ± A- 0 . 4 ± A
0.2 0.3 0.07 0.08 0.01 0.8 0.08 0.4 0.04 0.7
K1272 -1.3± A- 2 . 1 ± S- 0 . 6 ± A- 2 . 1 ± S- 0 . 4 ± A- 0 . 0 ± A- 0 . 7 ± A- 2 . 3 ± S- 1 . 3 ± A- 0 . 1 ± A
0.02 0.01 0.03 0.07 0.07 0.6 0.05 0.03 0.3 0.08
K1299 -2.0± S -2.5± S- 2 . 5 ± S -1.3± A +0.9± A- 1 . 1 ± A +1.0± A- 2 . 1 ± S +0.7± A +0.6± A
0 0.05 0.4 0 0.4 0.08 0.03 0 0.08 0.04
K193 -0.2± A -4.3± S -0.3± A- 0 . 5 ± A +0.2± A -4.4± S -1.4± A- 3 . 0 ± S- 0 . 6 ± A- 0 . 0 ± A
0.01 0.1 0.08 0.8 0.04 0.05 0 0.07 0.04 0.6
K237 -3.9± S -1.7± A- 0 . 2 ± A- 0 . 6 ± A +0.1± A -3.7± S -3.5± S- 2 . 4 ± S- 0 . 3 ± A- 0 . 4 ± A
0 0.09 0.07 0.04 0.7 0.1 0.9 0 0.6 0.06
J51 -5.5± S -3.3± S- 0 . 4 ± A- 0 . 6 ± A- 0 . 4 ± A -4.2± S -0.4± A- 0 . 5 ± A- 0 . 0 ± A +0.4± A
0.09 0.08 0.6 0.1 1.05 0.3 0.07 0.05 0.1 0.5
I93 -5.2± S -2.2± S- 1 . 0 ± A- 0 . 3 ± A- 1 . 0 ± A -4.6± S +0.1± A- 0 . 0 ± A +0.1± A- 0 . 8 ± A
0.1 0 0.2 0.03 0.09 0.07 0.4 0.09 0.9 0.1
MRSA120   -0.5± A- 0 . 0 ± A- 2 . 4 ± S- 2 . 2 ± S- 4 . 6 ± S -2.4± S ND - ND - ND - ND -
0.07 0.2 0.01 0.01 0.05 0.01
MRSA202 -0.6± A- 2 . 1 ± S- 0 . 6 ± A- 0 . 0 ± A- 0 . 9 ± A -5.7± S ND - ND - ND - ND -
0.06 0.02 0.5 0.02 0.01 0.5
Table 2. In vitro activity of arbekacin-based combinations against 7 hetero-VISA and 2 MRSA strains*
*The combination regimen that was the most significantly effective against each strain was represented as bold (p<0.05). ABK, arbekacin; VAN, van-
comycin; RFP, rifampin; A/S, ampicillin-sulbactam; TEI, teicoplanin; QDA, quinupristin-dalfopristin. S, synergic; A, additive/indifferent; ND, not done.Arbekacin-based Combinations Against Hetero-VISA 191
kacin for all strains were low, such re-growth seems not to
due to antimicrobial tolerance.
In this study, combination regimens of arbekacin with
vancomycin, teicoplanin, or ampicillin-sulbactam were syn-
ergistic against hetero-VISA and MRSA strains. In vitro
efficacy of the combination of arbekacin and vancomycin
against MRSA isolates in this study is consistent with pre-
vious data which showed the in vitro activity of combina-
tion regimens of arbekacin and vancomycin or daptomycin
against MRSA and hetero-VISA strains (14, 20, 29, 30).
Particularly, synergistic interaction of the combination of
arbekacin and ampicillin-sulbactam against MRSA and
hetero-VISA in the time-kill assay could provide the ratio-
nale of clinical uses of this combination in the treatment of
MRSA infections in Japan.
This study has some limitations. First, arbekacin concen-
trations used in this study (0.125-4 mg/L) was lower than
the maximally achievable concentration in healthy adults
after 100 mg of arbekacin by one-hour intravenous infusion
(7.56 mg/L, range 5.6-10 mg/L) (31). However, since strains
used in the study showed relatively low MIC (0.25-4 mg/L)
of arbekacin, 0.5× or 1× MIC concentration could not
simulate the actual situation in the human body. This low
concentration of arbekacin could affect the in vitro killing
efficacy of the drug shown in the study. Second, data from
the in vitro study may not reflect the in vivo drug efficacy
because in vitro model could not reflect the pharmacodynamic
features of antibiotics. We are now developing the experimen-
tal infection model by MRSA and hetero-VISA to evaluate
the in vivo efficacy of arbekacin.
In summary, in vitro data could suggest the possibility of
an alternative option in the treatment of MRSA infections
which could circumvent the selective pressure of glycopep-
tides in the clinical practice.
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